Suppr超能文献

镰状细胞病诱导CD8 T细胞中的染色质内陷和铁死亡以抑制抗肿瘤免疫。

Sickle cell disease induces chromatin introversion and ferroptosis in CD8 T cells to suppress anti-tumor immunity.

作者信息

Zhao Zilong, Hu Benxia, Deng Yalan, Soeung Melinda, Yao Jun, Bei Lanxin, Zhang Yaohua, Gong Pengju, Huang Lisa A, Jiang Zhou, Gao Jian, Peng Shuang, Nguyen Tina K, Karki Menuka, Lim Bora, Yee Cassian, Burks Jared K, Zhang Qing, Ma Li, Gao Jianjun, Tannir Nizar M, Han Leng, Yu Dihua, Wang Linghua, Curran Michael A, Gubbiotti Maria A, Genovese Giannicola, Gan Boyi, Li Wenbo, Msaouel Pavlos, Yang Liuqing, Lin Chunru

机构信息

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.

出版信息

Immunity. 2025 Jun 10;58(6):1484-1501.e11. doi: 10.1016/j.immuni.2025.04.020. Epub 2025 May 12.

Abstract

Understanding how genetic disorders affect CD8 T cells in the tumor microenvironment is key to improving cancer immunotherapy. Individuals with sickle cell disease (SCD), the most prevalent inherited blood disorder, have a higher risk of developing certain cancers than the general population, but the mechanisms driving this increased risk remain unclear. Our study revealed that SCD altered CD8 T cell 3D genome architecture, triggering ferroptosis and weakening anti-tumor immunity, thereby promoting tumor growth. Using murine and humanized SCD models, we found that disrupted chromosomal interactions in CD8 T cells reduced the expression of anti-ferroptotic genes, including SLC7A11 and hydrogen sulfide (HS) biogenesis genes, thereby increasing susceptibility to ferroptosis. Therapeutic restoration of HS concentration in SCD mice rescued SLC7A11 expression, mitigated ferroptosis, and enhanced immune and anti-tumor responses. These findings highlight the impact of inherited disorders on cancer immunity and suggest precision immunotherapy strategies for affected individuals.

摘要

了解遗传疾病如何影响肿瘤微环境中的CD8 T细胞是改善癌症免疫治疗的关键。镰状细胞病(SCD)是最常见的遗传性血液疾病,与普通人群相比,患有SCD的个体患某些癌症的风险更高,但导致这种风险增加的机制仍不清楚。我们的研究表明,SCD改变了CD8 T细胞的三维基因组结构,引发铁死亡并削弱抗肿瘤免疫力,从而促进肿瘤生长。使用小鼠和人源化SCD模型,我们发现CD8 T细胞中染色体相互作用的破坏降低了抗铁死亡基因的表达,包括SLC7A11和硫化氢(HS)生物合成基因,从而增加了对铁死亡的易感性。治疗性恢复SCD小鼠体内的HS浓度可挽救SLC7A11表达,减轻铁死亡,并增强免疫和抗肿瘤反应。这些发现突出了遗传性疾病对癌症免疫的影响,并为受影响个体提出了精准免疫治疗策略。

相似文献

1
Sickle cell disease induces chromatin introversion and ferroptosis in CD8 T cells to suppress anti-tumor immunity.
Immunity. 2025 Jun 10;58(6):1484-1501.e11. doi: 10.1016/j.immuni.2025.04.020. Epub 2025 May 12.
2
Bevacizumab induces ferroptosis and enhances CD8 T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9.
Acta Pharmacol Sin. 2024 Sep;45(9):1951-1963. doi: 10.1038/s41401-024-01299-4. Epub 2024 May 17.
3
Salvianic acid A enhances anti-PD-1 therapy by promoting HEV-mediated stem-like CD8 T cells infiltration in TNBC.
Cancer Immunol Immunother. 2025 Jun 30;74(8):256. doi: 10.1007/s00262-025-04116-x.
4
Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC.
J Adv Res. 2025 Jul;73:265-282. doi: 10.1016/j.jare.2024.08.021. Epub 2024 Aug 17.
5
9
M1 Macrophage-Derived TNF-α Promotes Pancreatic Cancer Ferroptosis Via p38 MAPK-ACSL4 Pathway.
Curr Mol Med. 2025 Jul 10. doi: 10.2174/0115665240374551250630075409.
10
Aristolochic acids-hijacked p53 promotes liver cancer cell growth by inhibiting ferroptosis.
Acta Pharmacol Sin. 2025 Jan;46(1):208-221. doi: 10.1038/s41401-024-01354-0. Epub 2024 Aug 1.

引用本文的文献

1
Ferroptosis in the tumor microenvironment: mechanisms, advances, and therapeutic perspectives.
Front Oncol. 2025 Aug 22;15:1650219. doi: 10.3389/fonc.2025.1650219. eCollection 2025.

本文引用的文献

1
Lack of SMARCB1 expression characterizes a subset of human and murine peripheral T-cell lymphomas.
Nat Commun. 2024 Oct 3;15(1):8571. doi: 10.1038/s41467-024-52826-0.
2
LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration.
Nat Metab. 2024 Sep;6(9):1756-1774. doi: 10.1038/s42255-024-01110-y. Epub 2024 Aug 15.
4
Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases.
Signal Transduct Target Ther. 2023 Dec 10;8(1):449. doi: 10.1038/s41392-023-01720-0.
5
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.
Nat Commun. 2023 Dec 1;14(1):7762. doi: 10.1038/s41467-023-43498-3.
6
Understanding Sickle cell disease: Causes, symptoms, and treatment options.
Medicine (Baltimore). 2023 Sep 22;102(38):e35237. doi: 10.1097/MD.0000000000035237.
7
A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.
Cancers (Basel). 2023 Jul 27;15(15):3806. doi: 10.3390/cancers15153806.
9
Renal Cell Carcinoma of Variant Histology: Biology and Therapies.
Hematol Oncol Clin North Am. 2023 Oct;37(5):977-992. doi: 10.1016/j.hoc.2023.04.019. Epub 2023 May 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验